Background/Objectives: Metastatic testicular germ cell tumor (mGCT) is a highly curable disease with first-line cisplatin-based combination chemotherapy. This study aims to evaluate the clinicopathological characteristics and survival outcomes of patients with metastatic testicular cancer in a nationwide multicenter cohort. Methods: This multicenter retrospective cohort study included 316 male patients diagnosed with mGCT who were treated with first-line cisplatin-based chemotherapy across 10 institutions in Turkey between 2011 and 2024. Clinical and pathological data, including International Germ Cell Cancer Collaborative Group (IGCCCG) risk classification, treatment details, and survival outcomes, were analyzed. Results: The median age of the cohort was 28 years, and 76.3% of patients were diagnosed with non-seminoma. According to IGCCCG risk stratification, 53.2% had good-risk, 25.3% intermediate-risk, and 21.5% poor-risk disease. Median follow-up was 38.4 months. Among patients with seminoma, the 5-year overall survival (OS) rate was 100% in the good-risk group and 87.5% in the intermediate-risk group. In patients with non-seminoma, 5-year OS rates were 96.6%, 86.9%, and 65.1% in the good-, intermediate-, and poor-risk groups, respectively. Among 125 patients who received salvage treatment, high-dose chemotherapy (HDCT) significantly improved survival in the International Prognostic Factors Study Group (IPFSG) very high-risk group (3-year OS: 55.0% vs. 16.3% with conventional-dose chemotherapy (CDCT), p = 0.007). Conclusions: This study provides the first large-scale nationwide dataset on mGCT outcomes in Turkey, demonstrating overall survival rates comparable to international cohorts. The findings emphasize the importance of a multidisciplinary approach, adherence to treatment guidelines, and optimal surgical interventions in improving patient outcomes.
31 May 2026 in Journal of Basic and Clinical Health Sciences
Background: Metastatic hormone-sensitive prostate cancer (mHSPC) requires accessible biomarkers for better prognostication. This study investigated the prognostic value of the alkaline phosphatase-to-albumin ratio (APAR) in mHSPC survival risk stratification.Methods: We retrospectively analyzed 128 mHSPC patients. A cut-off of 2.92 for APAR was determined via ROC analysis. Overall survival (OS) was assessed using Kaplan–Meier methods and multivariable Cox regression adjusting for standard prognostic factors, including tumor volume and Gleason score.Results: Patients with APAR ≥2.92 had significantly shorter OS compared to those with APAR
1 January 2026 in Eurasian Journal of Medical Investigation
Meme kanseri, kadınlarda en sık karşılaşılan malignite olup, biyolojik çeşitliliği nedeniyle alt gruplara ayrılarak tedavi edilmektedir. HER2 (human epidermal growth factor receptor 2) reseptörü, tedavi ve prognozda önemli bir biyobelirteçtir. Geleneksel olarak HER2 pozitif ve negatif olarak sınıflandırılan meme kanserlerinde, son yıllarda IHC +1 veya IHC +2 olup in situ hibridizasyon (ISH) negatif olan hastaları içeren "HER2 düşük ekspresyonlu" bir alt grup tanımlanmıştır. HER2 düşük tümörlerin, HER2 pozitif tümörlerden farklı biyolojik özellikler gösterdiği ve klasik kemoterapiye ek olarak anti-HER2 ajanlara sınırlı yanıt verdiği görülmüştür. Trastuzumab deruxtecan (T-DXd) gibi yeni nesil antikor-ilaç konjugatları bu alt grupta belirgin progresyonsuz sağkalım (progression free survival; PFS) ve genel sağkalım avantajı sağlamıştır. Ayrıca sacituzumab govitecan (SG) gibi diğer hedefe yönelik tedaviler de HER2 düşük ve HER2-0 hasta gruplarında umut vadetmektedir. Bununla birlikte, HER2 düşük ekspresyonun prognostik önemi, ideal tedavi sıralaması ve hasta seçim kriterleri gibi konular hâlâ araştırma alanıdır. Bu derlemede, HER2 düşük ekspresyonlu meme kanserinin tanı yöntemleri, biyolojik özellikleri ve güncel tedavi yaklaşımları detaylı şekilde ele alınmıştır.
Thymic epithelial tumors (TETs), comprising thymomas and thymic carcinomas, are rare, biologically heterogeneous thoracic malignancies with limited therapeutic advances since platinum-based regimens were adopted decades ago. Recent genomic and immunophenotypic profiling has uncovered recurrent genomic alterations and high programmed death-ligand 1 (PD-L1) expression, particularly in thymic carcinoma, yet few targeted or immunotherapies have achieved regulatory approval. This mini-review synthesizes current knowledge on TET heterogeneity and the genomic landscape, evaluates the clinical evidence supporting targeted agents and immune checkpoint inhibitors, and examines emerging biomarkers, including circulating tumor DNA. We also address practical barriers to precision oncology in TETs: challenges of next-generation sequencing implementation and cost in resource-limited settings; scarcity of large, biomarker-driven trials; and safety concerns unique to TETs (immune-related toxicity). Finally, we discuss the translational hurdles for antibody–drug conjugates and cellular therapies, limited validated cell surface targets, antigen heterogeneity, and preclinical model gaps and outline strategic paths forward to enable rational, safe, and equitable precision therapeutics for TET patients.
Background and Objectives: This study aimed to evaluate the effects of 24 h versus 46 h continuous 5-fluorouracil (5-FU) infusion durations on pathological response, progression-free survival (PFS), and overall survival (OS) in patients with gastric and gastroesophageal junction adenocarcinoma receiving a perioperative FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) regimen. Materials and Methods: A total of 300 patients who received a perioperative FLOT regimen were retrospectively analyzed. The patients were divided into two groups as those receiving 24 h and 46 h continuous 5-FU infusion. Clinicopathological characteristics were compared. Survival analyses were evaluated using the Kaplan–Meier method. Factors affecting pathological response were analyzed by logistic regression, and factors affecting survival were examined by Cox regression analysis. Results: Pathological response rates were found to be significantly higher in patients receiving 46 h 5-FU infusion (multivariate analysis: OR = 2.884; 95% CI: 1.619–5.138; p < 0.001). The probability of pathological response was found to be significantly lower in patients with baseline cT4 and advanced nodal stage. Median OS times were 41.23 months and 33.73 months in the 24 h and 46 h groups, respectively, with no significant difference detected between the groups (p = 0.371). In contrast, median PFS time was significantly longer in the 24 h group (38.47 months vs. 18.00 months; p < 0.001). However, in multivariate analysis, 5-FU infusion duration could not be demonstrated as an independent prognostic factor for PFS. Moderately and poorly differentiated tumors and an increased number of positive lymph nodes were found to be independent risk factors for progression. Conclusions: Although 46 h 5-FU infusion in the perioperative FLOT regimen was associated with a higher pathological response rate, this advantage was not reflected in survival outcomes. It is considered that the observed difference in PFS may stem from the clinicopathological heterogeneity between the groups. Prospective randomized studies are needed to determine the optimal 5-FU infusion duration.